Author

Kristin A. Kantautas

ORCID 0009-0003-2350-3073Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Genetic & Genomic Medicine· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:C. elegans· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:electronic health records· 1 Organism:human· 1 Assay:metabolomics· 1

Frequent Co-Authors

Ethan O. PerlsteiniD· 3 shared Akhilesh PandeyiD· 2 shared Éva MoravaiD· 2 shared Briannna M. Roel· 1 shared Claudia MaiosiD· 1 shared Douglas Smith· 1 shared Éric SamarutiD· 1 shared Frédéric Maxime VaziD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetic & Genomic Medicine

Ethan O. PerlsteinORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintJun 5, 2026

DHDDS-related juvenile parkinsonism is caused by impaired lipid metabolism, glycosylation, and mitochondrial dysfunction, which can be rescued by NAD⁺ treatment.

Irena Josephina Johanna Muffels, Kristin A. Kantautas, Georgia MacDonald…·Éva Morava

This study identifies mitochondrial dysfunction and metabolic impairments in DHDDS-related juvenile parkinsonism and shows that NMN treatment improves symptoms in patient-derived organoids and clinical cases.

DOI 10.64898/2026.05.28.26354198

humanproteomics

𝕏 PostBluesky

Cell BiologybioRxivPreprintJan 20, 2026

Repurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDG

Hiba Daghar, Seul Kee Byeon, Claudia Maios…·Kristin A. Kantautas

The paper develops a C. elegans model of SRD5A3-CDG and identifies atorvastatin as a potential repurposed therapy through a high-throughput screen.

1 citation

C. elegansexperimental assay

𝕏 PostBluesky

Systems BiologybioRxivPreprintAug 23, 2024

Industrializing yeast as a drug repurposing platform for inherited metabolic diseases

Mathuravani A. Thevandavakkam, Natalie E. Long, Briannna M. Roel…·Ethan O. Perlstein

This paper presents a yeast-based drug repurposing platform for inherited metabolic diseases, demonstrating its efficacy through case studies and showing potential to accelerate therapy development.

1 citation

yeastexperimental assay

𝕏 PostBluesky